Genzyme Corporation v. Ingenus Pharmaceuticals LLC
1:17-cv-00602
Overview
Parties
Defendant
Ingenus Pharmaceuticals LLC Operating Company
Represented By
2 Attorneys ListedBlank Rome LLP
1201 N. Market Street, Suite 800
Plaintiff
Sanofi-Aventis U.S. LLC Operating Company
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Southern Research Institute NPE (Individual / Inventor)
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Genzyme Corporation NPE (Individual / Inventor)
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5661136
2-halo-2'-fluoro ARA adenosines as antinoplastic agents
|
Filed: 1994-09-21
Issued: 1997-08-26
|
Expired (Term Ended)
+1211d PTA
Expires: 2018-01-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
High PTA (+1211 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).